Actelion's Tracleer misses Breathe-2 endpoint

Actelion (SWX:ATLN) said that in a 33-patient study, the

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE